Wall Street Journal Archives - Carey Danis & Lowe

Testosterone Gel Safety Poll Undermined by Medical Professionals

By | Pharmaceutical litigation, Testosterone, Uncategorized

testosteronegellawsuitThe New England Journal of Medicine (NEJM) recently conducted a community poll on testosterone gel safety that concluded on December 2, 2014. The purpose of the poll was to get a clearer understanding of where the NEJM readers, who are primarily medical professionals, stand on prescribing products like testosterone gels to treat signs of aging, also known as low testosterone, or low T.

According to a Wall Street Journal article about the poll, it appears that a medical group in support of testosterone therapy may have undermined the poll through an email campaign advocating use of testosterone products.

Though it was first thought that the emails were widely circulated among the entire NEJM community, the Wall Street Journal later made a correction to their article, clarifying that the emails distributed by this pro-testosterone therapy group reached only other members of the group.

Even so, this discovery is alarming, especially in light of the fact that some members of the group have received thousands of dollars in perks from pharmaceutical companies responsible for manufacturing testosterone therapy products.

Though the NEJM poll is not the final word on testosterone therapy safety, the results nevertheless provide important insight into how the medical field is handling the issue.

Currently, prescribing testosterone gels for low T is not highly regulated, as the U.S. Food and Drug Administration (FDA) is in the midst of deliberating how to move forward in regards to these products.

In fact, a clear indicator that testosterone gel regulation is lacking in the U.S. is the fact that nearly a quarter of the patients who use some form of testosterone therapy product received their prescriptions without having to undergo testosterone level evaluations, according to the Wall Street Journal. This is a startling fact in light of studies having found a solid link between testosterone gels and cardiovascular complications.

In Canada, the country’s drug regulator has wasted no time in demanding updates to testosterone drug labels to reflect cardiovascular risks.

Legal Assistance for Anyone Injured by Testosterone Gels

Carey Danis & Lowe is a St. Louis law firm that specializes in testosterone gel lawsuits.

Our defective drug lawyers are currently accepting testosterone gel cases. If you or someone you love has been injured by testosterone gels, our lawyers are available to walk you through your legal options and compensation eligibility during a free, no-obligation case evaluation.

Contact the law offices of Carey Danis & Lowe by phone at 800.721.2519, or by completing a confidential personal injury claim form.

Carey Danis & Lowe Weighs in on Testosterone Gel Safety

By | Pharmaceutical litigation, Testosterone, Uncategorized

St. Louis, Missouri (PRWEB) November 25, 2014

testosteroneAs a personal injury law firm with a focus on defective drug law, Carey Danis & Lowe have remained abreast of the news circulating on the topic of testosterone gel and testosterone-replacement therapy as they relate to patient health and safety. Testosterone gels have been placed under increased scrutiny over the past year, in large part due to a study published in the Journal of the American Medical Association (JAMA) in November 2013 whose findings showed an increase in the risk of heart attack and stroke in study participants who used testosterone.

Carey Danis & Lowe contends that, perhaps in response to the JAMA study, the Food and Drug Administration (FDA) recently made steps to address testosterone gel safety through appointing an advisory panel. This special panel of experts released their recommendations to the FDA in September 2014.

According to an article published by the Wall Street Journal in late October 2014, the panel recommended that the FDA complete two actions, the first to order drug makers to conduct studies on their particular testosterone products as they relate to cardiovascular health, and the second, to update testosterone product labeling to reflect the reality that extensive research does not exist validating the safety of testosterone products to treat low testosterone.*

The recommendations of the FDA panel introduce the right course of action, say Carey Danis & Lowe, defective drug lawyers. It is important to test testosterone gel and other testosterone products to better understand their impact on heart health. Furthermore, updating the product labeling is vital in providing healthcare providers and patients with the most up-to-date information on the safety of testosterone products, so that they can make informed health decisions.

Legal Assistance for Alleged Defective Drug Injuries

In addition to staying current on the FDA’s handling of testosterone gel, the legal team and medical professionals at Carey Danis & Lowe are also following the testosterone gel litigation taking place in a federal court in Illinois (U.S. District Court for the Northern District of Illinois, In re: Testosterone Replacement Therapy Product Liability Litigation, MDL no. 2545). As the St. Louis law firm provides legal assistance and representation to individuals who claim to have been injured by testosterone gel, Carey Danis & Lowe delivers their expert analysis on timely topics for the benefit of anyone interested in defective drug law and news.

Carey Danis & Lowe is available to review legal options, compensation eligibility, and health concerns with those who claim injury from testosterone gel products.
Carey Danis & Lowe can be reached by phone at 800.721.2519.

About Carey Danis & Lowe

Carey Danis & Lowe is a plaintiff’s litigation firm based in St. Louis, Missouri with law offices across the United States in Illinois, Missouri, and Florida. Carey Danis & Lowe specializes in defective drug and pharmaceutical litigation and class action lawsuits. The Carey Danis & Lowe team is comprised of experienced attorneys working alongside knowledgeable and professional staff that includes medical doctors, nurses, and information technology specialists. Contact Carey Danis & Lowe at 800.721.2519 for more information about our legal services.


Wall Street Journal, “In Men’s Fight Against Aging, How Much Risk to Take?”, Melinda Beck, October 27, 2014: http://bit.ly/wsj-testosterone-replacement-therapy

American Medical Systems Begins Vaginal Mesh Study

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

ams_transvaginal_mesh_lawsuit_settlementsAs mandated by the U.S. Food and Drug Administration (FDA), American Medical Systems (AMS) has started its transvaginal mesh study by enrolling its first participant. The transvaginal mesh manufacturer announced the enrollment in a press release published by the Wall Street Journal.

According to the press release, the AMS study will take place over a period of five years, with two years designated as an enrollment period, and the remaining three years allotted for tracking patient health. The study is to look at the AMS transvaginal mesh product, Elevate (TM) Anterior and Apical Prolapse Repair System.

Though news of the AMS transvaginal mesh study is a welcome announcement, such an in-depth examination of the health effects of transvaginal mesh for the treatment of pelvic organ prolapse (POP) would have best been conducted prior to releasing these types of products onto the market.

Carey Danis & Lowe Represents Victims

A law firm headquartered in St. Louis, Carey Danis & Lowe is dedicated to providing their expert legal assistance to victims of transvaginal mesh. Our team of defective medical device and personal injury lawyers understand the pain and suffering that individuals and families endure in the wake of injuries from a defective product. If you or someone you love has been injured by transvaginal mesh, work with a team of lawyers that are committed to your case.

Explore your legal options and compensation eligibility with a Carey Danis & Lowe lawyer today. Our initial consultations are free.

FDA Inspects American Medical Systems Headquarters

By | Defective Medical Device litigation, Transvaginal Mesh, Uncategorized

ams_transvaginal_mesh_lawsuit_settlementsThe parent company of American Medical Systems, the medical device manufacturer whose transvaginal mesh products are currently the subject of thousands of lawsuits in West Virginia, received a warning letter from the U.S. Food and Drug Administration (FDA) in February. Endo was dealt the warning letter following an inspection of an American Medical Systems headquarters located in Minnesota.

According to an article recently published in the Wall Street Journal, American Medical Systems has made efforts to improve their business practices according to the contents drawn up in the warning letter, which primarily concerned safety procedures.

As American Medical Systems works on corrective measures at their headquarters, the transvaginal mesh lawsuits targeted at them and their mesh products continue to pile up in a federal court in West Virginia. To date, there are currently well over 17,000 lawsuits filed in the American Medical Systems multidistrict litigation (MDL).

The next two American Medical Systems MDL status conferences have been canceled, according to the court’s website. However, the MDL will soon start the bellwether trial process, as the court is scheduled to hear two bellwether cases, with the first to begin on June 2, 2014 and the second on July 7, 2014.

Carey Danis & Lowe Investigating Mesh Cases

The defective medical device lawyers at Carey Danis & Lowe continue to hear from women who have been severely injured by defective transvaginal mesh products. Carey Danis & Lowe is a committed advocate of victims of defective medical devices. We offer free initial case evaluations, and encourage you to contact our law firm if you have been injured by defective transvaginal mesh.

Share your story with Carey Danis & Lowe today by calling 800.721.2519, or complete one of our confidential personal injury claim forms.

Takeda Pharmaceuticals Releases New Diabetes Drug with Bladder Cancer Causing Pioglitazone

By | Actos, Pharmaceutical litigation, Uncategorized

takeda_pharmaceuticals_actos_bladder_cancer_new_diabetes_drug_combination_alogliptinThe manufacturer of the diabetes drug Actos, a drug that is tied up in mounting complaints and lawsuits citing the development of bladder cancer, has received U.S. Food and Drug Administration (FDA) approval for a new diabetes drug known generically as alogliptin. The FDA approved three new alogliptin combination drugs for the treatment of type 2 diabetes along with an adjusted diet and exercise regimen.

Takeda has announced that it will release the three drug combinations onto the market beginning in the summer of 2013.

Takeda Pharmaceuticals, a Japanese pharmaceutical company, lost their patent over Actos, known generically as pioglitazone, back in August 2012. With more competition entering into the diabetes drug market, especially with generic versions of Actos, Takeda Pharmaceuticals has introduced three combinations of alogliptin, one of which includes pioglitazone, which is present in Actos.

The alogliptin and pioglitazone drug combination is known as Oseni.

A major concern with the release of Oseni is that, though it will be marketed as a separate drug from Actos, it still contains the same active ingredient present in Actos, known as pioglitazone, a notorious ingredient that has been linked to the development of bladder cancer.

As of yet, however, the only warning given for Oseni is that of congestive heart failure, which is similar to the safety alert the FDA released in August 2007 about Actos and congestive heart failure.

Though it may not be immediately apparent that Oseni proves to be just as harmful as Actos, it is easy to make such a deduction following the mountain of complaints and lawsuits that have sprouted up across the country pertaining to the development of bladder cancer. In light of this, it is egregious that Takeda Pharmaceuticals would release onto the market yet another drug containing an ingredient suspected of causing bladder cancer.

One possible motivation for Takeda’s lack of sensitivity to the harm caused by Actos and pioglitazone is the pharmaceutical giant’s efforts to increase profits. According to a Wall Street Journal article published in early February, Takeda has taken a huge hit in the marketplace with their profits dropping 14 percent. Furthermore, a Bloomberg News report cites that Takeda is anticipating a significantly lower net income through early 2015.

Lawyers at Carey Danis & Lowe are currently evaluating Actos bladder cancer cases. We are also closely monitoring Actos lawsuits being filed around the country. If you or someone you love has been injured by Actos, you and your loved one may be eligible to receive compensation.

For a free legal evaluation about your Actos case, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519.